Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair

25 Jan 2025

Abstract excerpt

BACKGROUND: Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39863903
DOI: 10.1186/s12964-025-02056-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repairPMID 39863903Read ↗

Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity Read ↗

ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian CancerSemantic proximity Read ↗

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian CarcinomasSemantic proximity Read ↗

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair PathwaySemantic proximity Read ↗

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read ↗

Activation of Wnt signaling promotes olaparib resistant ovarian cancerSemantic proximity Read ↗

RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.Semantic proximity Read ↗

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway InhibitorsSemantic proximity Read ↗

DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic OpportunitiesSemantic proximity Read ↗

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.